利拉鲁肽和西格列汀对胰岛素治疗血糖控制欠佳肥胖2型糖尿病患者的疗效比较  

Comparison of efficacy of liraglutide and sitagliptin in treatment of poorly controlled obese patients with type2diabetes mellitus

作　　者：吕玉立[1] 陆浩炎[1] LV Yu-li;LU Hao-yan(Department of Pharmacy, Hangzhou First People’s Hospital, Hangzhou 310006, China)

机构地区：[1]杭州市第一人民医院药学部,浙江杭州310006

出　　处：《中国生化药物杂志》2017年第12期44-45,共2页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的比较利拉鲁肽和西格列汀对胰岛素治疗血糖控制欠佳肥胖2型糖尿病患者的疗效。方法选取杭州市第一人民医院2014年7月～2016年2月收治的96例经胰岛素治疗后血糖仍控制不佳的肥胖2型糖尿病患者，随机分为利拉鲁肽组（n=48）与西格列汀组（n=48）。利拉鲁肽组患者给予注射利拉鲁肽，西格列汀组患者服用西格列汀。2组均治疗15w。比较2组治疗前后血糖、血脂、胰岛素功能及不良反应发生情况。结果2组FBG、HbA1c、2hPG及FIns水平、TG、HOMA-IR、HOMA-β较治疗前均有所改善，但利拉鲁肽组改善效果较西格列汀组更好（P＜0.05）。利拉鲁肽组不良反应发生率较西格列汀组更高（P＜0.05）。结论利拉鲁肽和西格列汀对胰岛素治疗血糖控制不佳肥胖2型糖尿病的疗效确切；相比而言，利拉鲁肽在降糖、降脂及提高胰岛素功能等方面占优势；2种药物安全性均较高，但利拉鲁肽于胃肠道方面不良反应较多。Objective To investigate the efficacy of liraglutide and sitagliptin in the treatment of poorly controlled obese patients with type2diabetes mellitus.Methods96patients with obese type2diabetes who were still underdeveloped with insulin after insulin treatment from July2014to February2016were randomly divided into liraglutide group(n=48)and siglitide group(n=48).After treatment,blood glucose,blood lipid and insulin function and adverse events were compared between two groups.Results After treatment,the levels of FBG,HbA1c,2hPG,FIns,TG,HOMA-IR and HOMA-βwere all better than pre-treatmet,and liraglutide group was better than sitagliptin group(P<0.05).The incidence of adverse reactions in the liraglutide group was higher than that in the sitagliptin group(P<0.05).Conclusion Liraglutide and sigmatidine are effective in the treatment of poorly controlled obesity type2diabetes mellitus with insulin.In contrast,liraglutide is dominant in hypoglycemic,lipid lowering and insulin resistance.Drug safety are high,but liraglutide in the gastrointestinal tract more adverse reactions.

关 键 词：利拉鲁肽 西格列汀 血糖控制欠佳 肥胖2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]